Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Purpose Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. Methods RAS mutant genes in solid biopsy (before...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2022-06, Vol.24 (6), p.1209-1214
Main Authors: Fernández Montes, A., Élez, E., Vivancos, A., Martínez, N., González, P., Covela, M., de la Cámara, J., Cousillas, A., Méndez, J. C., Graña, B., Aranda, E.
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Brief
Brief Research Article
Clone Cells - pathology
Colonic Neoplasms - drug therapy
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - pathology
Fluorouracil - therapeutic use
Humans
Medicine
Medicine & Public Health
Mutation
Oncology
Panitumumab - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. Methods RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies). Results Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test). Conclusion Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.
ISSN:1699-3055
1699-048X
1699-3055
DOI:10.1007/s12094-021-02767-7